Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPVI-inhibitory antibodies
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GPVI-inhibitory antibodies are a program of monoclonal antibody Fab fragments being developed by AdvanceCOR in collaboration with MorphoSys for the treatment of arterial thrombosis. These antibody fragments were identified from MorphoSys's Ylanthia-Fab library and are designed to target Glycoprotein VI (GPVI), a key receptor for collagen on the platelet surface. By blocking the interaction between collagen and GPVI, the antibodies inhibit collagen-induced platelet activation and thrombus formation at the site of vascular injury. Preclinical data suggest that this approach can effectively prevent arterial thrombosis without increasing the risk of bleeding, as general hemostasis remains largely unaffected. Additionally, the program has shown potential in animal models for the prevention of abdominal aortic aneurysm formation.
- Other names
- anti-GPVI monoclonal antibody Fab fragmentsanti-GPVI antibodies
02
Targets
GPVI (Platelet glycoprotein VI)
Beyond the preview
Go deeper on GPVI-inhibitory antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPVI-inhibitory antibodies.